SCHEMBL3115462

SCHEMBL3115462

CCCCCn1c(=O)n(CCCc2nc3ccccc3n2CC)c(=O)c2[nH]c(Cl)nc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.47
▸ LMNA P02545 2/20 0.47
▸ SIRT1 Q96EB6 1/20 0.46
▸ SIRT3 Q9NTG7 1/20 0.46
▸ SIRT5 Q9NXA8 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ GAA P10253 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ ADORA2A P29274 2/20 0.43
▸ ADORA2B P29275 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ PDE4A P27815 1/20 0.43
▸ PDE4B Q07343 1/20 0.43
▸ PDE4C Q08493 1/20 0.43
▸ PDE4D Q08499 1/20 0.43
▸ MEN1 O00255 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13247876 0.81 PGR (0.50) SMN1; SMN2GAAKDM4EADORA2AADORA2B
SCHEMBL3115314 0.81 CYP2C19 (0.55) GAAKDM4EADORA2AADORA2BALDH1A1
SCHEMBL3115718 0.80 ADORA2A (0.55) SIRT1SIRT3SIRT5KDM4EADORA2A
SCHEMBL3116553 0.79 ADORA2B (0.46) KDM4EADORA2AADORA2BALDH1A1CYP1A2
SCHEMBL13247870 0.79 ADORA2B (0.44) TP53LMNAADORA2AADORA2BADORA1
SCHEMBL3106241 0.79 ADORA2B (0.58) SIRT1SIRT3SIRT5KDM4EADORA2A
SCHEMBL3620246 0.79 SIRT1 (0.61) SIRT1SIRT3SIRT5KDM4EADORA2A
SCHEMBL13247860 0.79 PCK1 (0.53) KDM4EADORA2AADORA2BALDH1A1CYP1A2
SCHEMBL13247888 0.79 RAB9A (0.48) LMNASIRT1SIRT3SIRT5SMN1; SMN2
SCHEMBL843582 0.79 ADORA2B (0.54) SIRT1SIRT3SIRT5KDM4EADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 — — US disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 — — US disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 — — US disclosed
WO-2007017262-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2007-02-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS XDH, GPR84, GPR88 TP53 4012/4885LMNA 1625/4885SIRT1 1684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback